Niger vs Sierra Leone: Statin use vs. average non-HDL cholesterol levels
Niger
2.8
in 2018
Sierra Leone
2.8
in 2018
Niger rank
163rd
Sierra Leone rank
163rd
Statin use vs. average non-HDL cholesterol levels over time
- Niger
- Sierra Leone
How they compare
Niger currently reports 2.8 against 2.8 in Sierra Leone, a difference of 0.
Across all 39 years both countries report, Sierra Leone has been ahead every year.
Niger ranks 163rd and Sierra Leone ranks 163rd of 191 countries.
Sierra Leone has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Niger | Sierra Leone | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.33 | 2.55 | 0.22 | Sierra Leone |
| 1990s | 2.45 | 2.6 | 0.15 | Sierra Leone |
| 2000s | 2.58 | 2.69 | 0.11 | Sierra Leone |
| 2010s | 2.76 | 2.8 | 0.0444 | Sierra Leone |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Niger or Sierra Leone?
- Niger, at 2.8 against 2.8 in Sierra Leone as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Niger and Sierra Leone?
- 0, with Niger ahead.
- How many years of comparable data are there for Niger and Sierra Leone?
- 39 years are reported by both, from 1980 to 2018.
- How do Niger and Sierra Leone rank globally for statin use vs. average non-hdl cholesterol levels?
- Niger ranks 163rd and Sierra Leone ranks 163rd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.